SS Innovations International (SSII) FDA Approvals $3.89 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.92 +0.03 (+0.80%) As of 05/22/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SS Innovations International's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by SS Innovations International (SSII). Over the past two years, SS Innovations International has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as SSi. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. SSi Mantra surgical robotic system FDA Regulatory Events SSi Mantra surgical robotic system is a drug developed by SS Innovations International for the following indication: robotic surgery. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Pre-Marketing Filing - October 2,2025Pre-Marketing Filing Drug: SSi Mantra surgical robotic systemAnnounced Date: October 2, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: robotic surgeryAnnouncementSS Innovations International anticipates submitting a 510(k) premarket notification to the United States Food and Drug Administration (the "FDA") for the SSi Mantra for multiple specialty indications in the fourth quarter of 2025.AI SummaryIn September 2025, SS Innovations completed a human factors validation study at Johns Hopkins Hospital for its SSi Mantra robotic system. This study provides essential evidence that the system meets FDA requirements for usability and patient safety, and it will be a key part of the company’s upcoming regulatory filing. SS Innovations anticipates submitting a 510(k) premarket notification to the U.S. Food and Drug Administration in the fourth quarter of 2025. The company has engaged RQM+, a specialized medical technology contract research organization, to support the submission process. Based on standard review timelines, and excluding any additional information requests, FDA clearance could be granted in the first half of 2026. If cleared, the SSi Mantra could soon be marketed in the United States, advancing SS Innovations’ mission to make advanced, cost-efficient surgical robotics more accessible to hospitals and patients nationwide.Read AnnouncementProvided Update - October 2,2025Provided Update Drug: SSi Mantra surgical robotic systemAnnounced Date: October 2, 2025Indication: robotic surgeryAnnouncementSS Innovations International announced that the Company successfully completed a human factors validation study for its SSi Mantra surgical robotic system (the "SSi Mantra") at Johns Hopkins Hospital in September 2025AI SummaryIn September 2025, SS Innovations International successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital. The study proved that the system meets key FDA requirements for usability and patient safety, marking a significant step toward U.S. regulatory approval. Building on this milestone, the company plans to submit a 510(k) premarket notification to the FDA in the fourth quarter of 2025. SS Innovations has partnered with RQM+, a leading MedTech-focused CRO, to guide the submission process. If the FDA agrees that SSi Mantra can be marketed, clearance could follow in the first half of 2026 under standard review timelines. SS Innovations designs user-friendly robotic surgery solutions for hospitals. The SSi Mantra system has been installed in several countries, supporting thousands of procedures and aiming to make advanced robotic surgery more accessible.Read Announcement SS Innovations International FDA Events - Frequently Asked Questions Has SS Innovations International received FDA approval? As of now, SS Innovations International (SSII) has not received any FDA approvals for its therapy in the last two years. What drugs has SS Innovations International submitted to the FDA? In the past two years, SS Innovations International (SSII) has reported FDA regulatory activity for SSi Mantra surgical robotic system. What is the most recent FDA event for SS Innovations International? The most recent FDA-related event for SS Innovations International occurred on October 2, 2025, involving SSi Mantra surgical robotic system. The update was categorized as "Provided Update," with the company reporting: "SS Innovations International announced that the Company successfully completed a human factors validation study for its SSi Mantra surgical robotic system (the "SSi Mantra") at Johns Hopkins Hospital in September 2025" What conditions do SS Innovations International's current drugs treat? Currently, SS Innovations International has one therapy (SSi Mantra surgical robotic system) targeting the following condition: robotic surgery. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AC Immune FDA EventsAgios Pharmaceuticals FDA EventsAssembly Biosciences FDA EventsBriacell Therap FDA EventsBioLineRx FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsOncolytics Biotech FDA EventsRegeneron Pharmaceuticals FDA EventsAbbVie FDA EventsMerck & Co., Inc. FDA EventsAgenus FDA EventsAdagio Medical FDA EventsAktis Oncology FDA EventsAkari Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Soleno Therapeutics FDA Events TransMedics Group FDA Events AxoGen FDA Events NovoCure FDA Events Pulse Biosciences FDA Events PROCEPT BioRobotics FDA Events Inspire Medical Systems FDA Events iRadimed FDA Events Artivion FDA Events Alpha Tau Medical FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:SSII last updated on 10/2/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SS Innovations International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SS Innovations International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pre-Marketing Filing - October 2,2025Pre-Marketing Filing Drug: SSi Mantra surgical robotic systemAnnounced Date: October 2, 2025Target Action Date: Q4 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: robotic surgeryAnnouncementSS Innovations International anticipates submitting a 510(k) premarket notification to the United States Food and Drug Administration (the "FDA") for the SSi Mantra for multiple specialty indications in the fourth quarter of 2025.AI SummaryIn September 2025, SS Innovations completed a human factors validation study at Johns Hopkins Hospital for its SSi Mantra robotic system. This study provides essential evidence that the system meets FDA requirements for usability and patient safety, and it will be a key part of the company’s upcoming regulatory filing. SS Innovations anticipates submitting a 510(k) premarket notification to the U.S. Food and Drug Administration in the fourth quarter of 2025. The company has engaged RQM+, a specialized medical technology contract research organization, to support the submission process. Based on standard review timelines, and excluding any additional information requests, FDA clearance could be granted in the first half of 2026. If cleared, the SSi Mantra could soon be marketed in the United States, advancing SS Innovations’ mission to make advanced, cost-efficient surgical robotics more accessible to hospitals and patients nationwide.Read Announcement
Provided Update - October 2,2025Provided Update Drug: SSi Mantra surgical robotic systemAnnounced Date: October 2, 2025Indication: robotic surgeryAnnouncementSS Innovations International announced that the Company successfully completed a human factors validation study for its SSi Mantra surgical robotic system (the "SSi Mantra") at Johns Hopkins Hospital in September 2025AI SummaryIn September 2025, SS Innovations International successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital. The study proved that the system meets key FDA requirements for usability and patient safety, marking a significant step toward U.S. regulatory approval. Building on this milestone, the company plans to submit a 510(k) premarket notification to the FDA in the fourth quarter of 2025. SS Innovations has partnered with RQM+, a leading MedTech-focused CRO, to guide the submission process. If the FDA agrees that SSi Mantra can be marketed, clearance could follow in the first half of 2026 under standard review timelines. SS Innovations designs user-friendly robotic surgery solutions for hospitals. The SSi Mantra system has been installed in several countries, supporting thousands of procedures and aiming to make advanced robotic surgery more accessible.Read Announcement
